

University of Szeged
Albert Szent-Györgyi Medical School
Doctoral School of Clinical Medicine

Adaptive radiotherapy in different tumor sites

PhD Thesis

Zoltán Végváry, M.D.

Supervisor(s):

Katalin Hideghéty, M.D., Ph.D., Habil



Szeged

2025

1. Introduction

Adaptive radiotherapy (ART) approaches have been in the focus of research as part of radiation oncology development since the last three decades. Among numerous factors contributing to the advancement the implementation of modern image-guidance into treatment delivery has a major importance. Recently, image-guided ART (IGART) techniques have been widely used in different tumor sites, including glioblastoma (GBM) and locally advanced cervical cancer (LACC) as well.

The advent of various forms of high-tech volumetric imaging has opened up the possibility of defining and following target and normal structures in the brain with high resolution prior to and during a course of radiation therapy (RT). Several studies have investigated spatial and dosimetric changes in critical structures during treatment for different cancer types, but much less research has been performed on RT of the brain, which has great anatomical constancy due to the closed skull volume and lack of organ movement. However, tumor volume, the surgical cavity, the peritumoral region and several sensitive brain structures are assumed to undergo slow but evident changes (e.g. hemorrhage, edema and shift of anatomical structures) owing to the development of radiation-related reactions and residual tumor response. The importance of such anatomical changes during the course of RT increases if growing numbers of small substructures [target and organs at risk (OARs)] are defined for dose prescription. Glioblastoma is a tumor that invades surrounding tissues aggressively, becomes infiltrative and spreads into different regions of the brain. Defining the clinical target volume (CTV) on postoperative images is therefore a highly challenging task. Recently, advanced imaging techniques have been recommended to define the volume of the tumor mass, such as different sequences of magnetic resonance imaging (MRI) and amino acid-based positron-emission tomography (PET) images. These imaging strategies support ART workflows that account for dynamic anatomical and biological changes, thereby improving treatment precision and outcomes in GBM. Repeated imaging during the course of RT contributes to refining the accuracy of the planning target volume (PTV): postoperative changes, such as edema and surgical cavity evolution, tend to stabilize over time, allowing for a clearer visualization of the residual tumor. While GBM management highlights the importance of repeated imaging for ART, the need for adaptation is arguably even more pronounced in cervical cancer. This disease continues to be a significant health issue and cause of cancer morbidity and mortality. Radiotherapy, especially when using the IGART approach, plays a crucial role in improving outcomes. It is estimated that by implementing an IGART technique, 5-year disease-free survival will be more than 90% among

patients with locoregional disease. While early-stage cervical cancer can be cured with surgery or even with RT alone in certain clinical circumstances, the standard curative treatment for LACC is concomitant chemoradiotherapy (CRT). Intracavitary (IC) or combined intracavitary/interstitial (IC/IS) brachytherapy (BT) has been an essential component of the IGART approach in the last decade. Due to excellent soft tissue resolution providing additional information regarding residual tumor extent, environmental propagation, and surrounding normal anatomy, MRI-based image-guided adaptive BT (IGABT) has become the gold standard curative treatment for LACC. The EMBRACE-II was launched in 2016 as the first prospective multicenter interventional study aiming at uniform target concept and dose prescription protocol for MRI-guided IGABT to further improve efficiency and reduce treatment-related moderate and severe morbidity. Since MRI-guided IGABT provides individually inhomogeneous dose distribution and the possibility of dose escalation in large and irregular volumes based on complex applicator arrangements and 3D treatment planning, this sophisticated technique ensures a superior outcome reinforced by the excellent clinical results from the previous EMBRACE studies.

2. Aims

- 2.1. To evaluate and validate the institutional protocol for target volume definition in the RT of high-grade gliomas, with a focus on the integration of multimodal imaging and adaptive planning strategies.
- 2.2. To analyze the relationship between postoperative RT parameters - particularly GTV and PTV - and clinical outcome, overall survival (OS) in patients with high-grade gliomas.
- 2.3. To investigate the potential of the use of repeated CT/MRI during two-phase RT delivery and adaptation of the structure definition for replanning during postoperative/curative CRT in GBM patients and to evaluate the impact of changes on dosimetry and clinical outcomes.
- 2.4. To analyze our first findings on both the dosimetry and treatment-related toxicity aspects in LACC patients treated with curative CRT and IGABT boost depending on the BT technique applied (MRI based vs non-MRI based).

3. Patients and methods

3.1. Adaptive Radiotherapy for Glioblastoma Multiforme - The Impact on Disease Outcome

3.1.1. Study characteristics

Our retrospective analysis included patients diagnosed with histologically proven GBM undergoing postoperative/definitive CRT after neurosurgical intervention (biopsy or tumor resection). Patients were treated with 75 mg/m² temozolomide each day during RT, with a 60 Gy total dose administered in two phases (40 Gy + repeated planning CT/MRI-based replanning of a 20 Gy boost) conventionally fractionated at 2 Gy per fraction.

3.1.2. Contouring and treatment planning

Patients were positioned and fixed using a 3-point individual thermoplastic mask, with a CT scan taken with slice thickness of \leq 5 mm with the patient in a supine position. The GTV and PTV were defined on the primary CT using pre- and postoperative MRI images. Registration and contouring were performed with Advantage SIM software (version 4.7; General Electric Healthcare, Chicago, IL, USA). Contouring was performed in axial reconstructions of the CT data set after MRI-CT image fusion. The PTV margin around the GTV on the preoperative gadolinium-enhanced T1-weighted MRI sequence was defined according to our institutional protocol based on the actual RTOG contouring guidelines. Around the GTV, a 20 mm margin was created encompassing the peritumoral edema defined on the basis of postoperative T2-FLAIR MRI. In the case of excessive edema, the margin was adapted manually in individual cases. All plans were made and optimized in the Xio Planning System (version 4.7; Elekta, Stockholm, Sweden). The PTV was treated with 3-dimensional conformal RT or intensity-modulated RT (IMRT) up to 40 Gy in 20 fractions with regular position control using portal imaging or cone-beam CT (CBCT). After the first period of study, a second planning CT or, more recently, MRI was performed. GTV1 and PTV1 were defined on the secondary planning CT. When an MRI was taken, image registration was applied for delineation of GTV1 and PTV1 on the planning CT. PTV1 was assigned by adding a 10 mm margin around GTV1. The PTV1 volume was treated with 3D-conformal RT/IMRT delivering an additional 20 Gy in 10 fractions.

3.1.3. Statistical analysis

The primary endpoint was OS and target-volume parameters. Overall survival was measured from the date of histological diagnosis to the date of death from any cause. Patients who

developed none of these time-to-event endpoints were censored on the date of their last follow-up. Survival distributions and median survival data were estimated using the Kaplan–Meier method, and comparisons were performed based on the log-rank test for categorical characteristics. Cox proportional hazards regression models were fitted to examine the association of RT parameters with OS. Variables with p-values of less than 0.05 in the univariate analysis were selected for the multivariate Cox proportional hazards model. Statistical analysis was performed using the SPSS statistical analysis software package (version 20; IBM, Armonk, NY, USA). Statistical significance was set at a threshold of $p < 0.05$.

3.2. MRI-based image-guided adaptive brachytherapy for locally advanced cervical cancer in clinical routine: a single-institution experience

3.2.1. Background of study

We introduced the IGART technique in routine practice in our department at the end of 2015 for the definitive CRT of LACC patients. As a next step, we set out to introduce and adapt the recommendations of the EMBRACE-II protocol. For various reasons, not all patients received MRI-based IGABT during the procedure. With our retrospective study we intended to analyse radiotherapy-related parameters and the treatment's feasibility based on acute toxicity in two cohorts of patients comparing MRI-based IGABT versus CT only (non-MRI-based) BT boost as part of the definitive treatment for LACC. Inclusion criteria used the stage IB-IVA International Federation of Gynecology and Obstetrics (FIGO) 2009 system and included histologically proven squamous cell carcinoma, adeno-squamous carcinoma, or adenocarcinoma of the uterine cervix and the completion of curative CRT and BT. All patients underwent a gynecologic examination, additional cystoscopy and/or rectoscopy if organ involvement was suspected, and abdomino-pelvic MRI for pelvic staging at baseline. A diagnostic PET/CT scan was performed for the accurate assessment of lymph node involvement and exclusion of distant metastases. A second pelvic MRI was done on the fifth week of CRT in all cases to assess tumor response before the BT boost. During the MRI, contrast medium in the vagina was applied for better visualization.

3.2.2. Teletherapy technique

For external beam RT (EBRT), all patients went through similar treatment planning and delivery procedures. Patients were asked to empty their bowel before the treatment planning CT and each treatment session thereafter. Likewise, as a special bladder protocol, patients were instructed to urinate first, then drink 500 mL water in 30 min. Patients were positioned on the abdominal/pelvic module of the All In One (AIO) Solution (Orfit, Wijnegem, Belgium) and

fixed with the Pelvicast System (Orfit, Wijnegem, Belgium). Three series of non-contrast CT scans were taken (GE Healthcare Discovery™ RT CT, GE Healthcare, Chicago, IL, United States) from the top of the kidneys to the distal edge of the inguinal regions with an empty (0 min), comfortably filled (30 min), and full bladder (45 min). Diagnostic T2 weighted ($T2_w$) MRI and PET/CT scans were fused to the treatment planning CT for better target definition. The delineation of the volumes of interest was based on the guidelines of the EMBRACE-II study. Cumulative EBRT + IGABT 2Gy/fraction equivalent dose (EQD2) was calculated with the linear quadratic model using $\alpha/\beta = 10$ for target volumes and $\alpha/\beta = 3$ value for OARs. A total dose of 45 Gy was delivered to the PTV in 1.8 Gy/fraction daily doses. A simultaneously integrated boost (SIB) dose was applied to pathological lymph nodes to a total dose of 55 Gy if the parailiac lymph node region (PIL) was affected and 57.5 Gy if the para-aortic lymph node region (PAO) was affected. Radiation therapy was delivered with a comfortably filled bladder according to the bladder protocol. In all cases, a 5-field or 7-field inverse IMRT planning technique was applied using the Eclipse v13.6 planning system (Varian Oncology Systems, Palo Alto, CA, United States). Treatment was delivered with a Varian TrueBeamSTx or VitalBeam (Varian Oncology Systems, Palo Alto, CA, United States) linear accelerator equipped with high-definition (HD) 120 or Millenium120 multileaf collimator performing daily CBCT verification and couch repositioning referring to bony anatomy.

3.2.3. Concomitant chemotherapy

A total of five cycles of concomitant 40 mg/m^2 cisplatin per week chemotherapy was delivered during the EBRT. Possible dose reduction or withholding was based on continuous monitoring of blood cells and kidney function using the calculation of estimated glomerular filtration rate (eGFR) (Cockcroft-Gault formula).

3.2.4. Brachytherapy technique

Following CRT, patients had three or four BT boost treatments, based on the cumulative target doses in the various target volumes and OAR dose constraints. If the risk of overlapping the hard dose constraint of the OAR at the fourth BT session was foreseen, the BT boost dose was delivered in three sessions only. The delivery of two fractions on consecutive days and another two fractions a week later was aimed at in order to complete the RT procedure within 50 days. Before the BT session patients received an enema. A Foley catheter was inserted into the bladder and the bladder was filled with 50–100 mL of physiological saline. The volume was maintained during treatment to ensure reproducibility. In case of IC treatment, minor opiate tramadol and muscle relaxant premedication were applied 20 min before application. For the

IC/IS procedure, patients were provided epidural analgesia during the intervention, which was maintained if the applicators and the needles remained in the patient for the consecutive BT session the next day. IC/IS BT was applied only in the MRI-based IGABT group if significant residual tumor volume or parametrial infiltration was present at the time of the BT. In the non-MRI-based BT cohort, patients were treated with the simple IC technique. CT- and MRI-compatible Ring or 3D Interstitial Ring Applicator sets (Varian Oncology Systems, Palo Alto, CA, United States) were used for all patients. The maintenance of the geometry of the applicator towards the target volume was ensured by a tight vaginal packing aimed at pushing away the rectum and bladder and fixing the applicator against the cervix. The packing was filled with ultrasound gel to make it distinguishable from the vagina at planning. The applicator was also fixed with bandages to the patient. A special CT/MR-compatible stretcher (Spinal board BAR025, Fazzini, Italy) was used for patient transportation. The patient stayed on that device in a comfortable supine position throughout the procedure including verification and dose delivery. After inserting the applicator(s) in all cases, a non-contrast CT series with 2.5 mm slice thickness was acquired for safety reasons and to check the applicator's position. CT verification was used before BT delivery for safety, quality assurance, and planning purposes even if an MRI was not performed. Patients receiving MRI-based individualized IGABT were then transferred with the applicator *in situ* to the MRI unit before the first and third BT sessions at a minimum. CT and MRI images were fused with rigid registration of soft tissues for quality control and planning purposes. Adaptive target volume definition and treatment planning objectives were performed in accordance with the International Commission on Radiation Units and Measurements (ICRU) 89 recommendations. The following BT target and OAR volumes were segmented: residual GTV (GTVres), high-risk CTV (CTVHR), bowel, bladder, sigmoid and rectum. For dose recording, right and left Point A were indicated. CTVHR and GTVres and OARs were delineated in an applicator *in situ* T2w MRI sequence. The latest treatment planning MRI was reused for contouring with superimposition if the succeeding second and/or fourth BT fraction was CT-based only. In the non-MRI based BT group, non-contrast CT scans were used for delineation and previous (pre-radiotherapy and pre-BT) MRI images assisted contouring. CTVHR and OARs were delineated with adaptation to the GYN GEC-ESTRO guidelines, however, no GTVres was contoured. MRI images acquired during the fifth week of EBRT helped target definition without performing CT-MRI fusion. The BrachyVision TPS v13.6 planning system (Varian Oncology Systems, Palo Alto, CA, United States) was utilized for treatment planning. During optimization, first the built-in automatic option of the planning system was used, and then, taking into account the unique anatomical conditions, the plan was

manually refined in accordance with the dosimetric goals. All patients were treated with a Varian Gammamed Plus iX (Varian Oncology Systems, Palo Alto, CA, United States) high dose-rate (HDR) afterloader.

3.2.5. *Toxicity registration*

Treatment-related acute morbidity was registered on a weekly basis according to the Common Terminology Criteria for Adverse Events (CTCAE v. 4.0). Clinical data on treatment-related acute skin, gastro-intestinal, genito-urinary, or hematologic toxicity and kidney function impairment was collected, and the worst toxicity grade within a category was counted in each case.

3.2.6. *MRI-based quantitative tumor regression evaluation*

Based on the T2w MR image series, a quantitative tumor regression analysis was performed for the MRI-based IGABT cohort during the treatment process. The initial GTV (GTVinit) was evaluated in the first diagnostic MRI while the GTVres volumes were assessed in both the pre-BT MRI and subsequent applicator *in situ* MRI sequences.

3.2.7. *Statistical analysis*

Continuous data were expressed as mean \pm standard deviation (SD) values if appropriate. Tumor characteristics in the two cohorts were compared with an independent sample t-test for the continuous and Chi-squared test for the categorical variables. An independent sample t-test was used to analyze the various dose parameters between the treatment groups. Statistical software IBM SPSS statistics version 26.0 (SPSS Inc., Chicago, IL, United States) was used for statistical analysis. P-values <0.05 were regarded as statistically significant.

4. Results

4.1. *Adaptive Radiotherapy for Glioblastoma Multiforme - The Impact on Disease Outcome*

Forty-three consecutive patients with GBM treated at the Department of Oncotherapy University of Szeged, Hungary, between January 2013 and June 2016 were selected for a retrospective study. The average age of the 43 patients (19 males and 24 females) was 58.6 (range=12-85) years. Thirty-nine patients were treated with concurrent temozolomide chemotherapy during RT followed by temozolomide monotherapy, and four patients received only RT. All the patients underwent surgical tumor removal, with the tumor type confirmed by histology. The extent of the tumor removal of the entire study group was by subtotal resection

in the majority of cases (N=27). The O-6 methylguanine DNA methyltransferase (MGMT) status was available for 33/43 tumor samples for the present analysis and 17 were defined as being promoter region methylated by immunohistochemistry. The average time to planning CT after surgery was 2.8 (range=0.7-5.1) weeks. RT generally started 1 week after the planning CT, thus the mean time interval between surgery and CRT was 29.1 (range=5-59) days. All the patients had an additional (secondary) replanning CT/MRI (mean=3.9, range=3.7-4.0 weeks) after the start of RT [mean=7.7 (range=5.3-14.3) weeks after surgery], which was registered to the initial (primary) planning CT.

The initial size of the GTV was strongly inversely correlated with OS. The patients were separated for the Kaplan–Meier analysis into two groups according to the mean GTV size: ≤ 99 cm³ and >99 cm³. The median OS was 25.33 months (95% CI=19.59-35.27 months) for the first group and 15.21 months (95% CI=10.82-22.27 months) for the second, corresponding to a hazard ratio (HR) of 1.006 (95% CI=1.00-1.01, p=0.031). Using the average value as cut-off point, the PTV did not exhibit a correlation with survival. Median OS was 15.21 months (95% CI=15.06-31.34 months) in the first group and 19.12 months (95% CI=15.64-28.67 months) in the second group corresponding to an HR of 1.001 (95% CI=0.99-1.01, p=0.910). Anatomical changes in the brain and tumor growth or shrinkage occurred during RT. The GTV volume change (Δ GTV=GTV₁–GTV) during RT was correlated with OS. The median OS was 25.33 months (95% CI=21.68-35.28 months) in the group with Δ GTV<0 cm³, i.e. GTV regression, and 11.10 months (95% CI=10.63-22.69 months) in the group with Δ GTV ≥ 0 cm³, i.e. no change or progression of GTV, corresponding to an HR of 1.006 (95% CI=0.99-1.01, p=0.040). The recontouring and change of PTV was significantly different between the two groups: Patients with Δ PTV ≤ 183 cm³ and those with Δ PTV >183 cm³. The median OS was 12.06 months (95% CI=11.63-22.91 months) for the first group and 28.98 months (95% CI=22.36-38.82 months) for the second, corresponding to an HR of 1.001 (95% CI=0.99-1.01, p=0.026). The type of surgery had a significant impact on survival, patients who underwent biopsy had a mean survival of 6.97 months, those with subtotal tumor resection 20.5 months and with gross tumor resection of 25.33 months (p=0.009) respectively. A Kaplan–Meier analysis of the time from surgery to the start of CRT and OS revealed that CRT started within 27 days resulted in a significantly higher mean OS (26.48 vs. 15.21 months, p=0.046). Our results demonstrated that MGMT promoter methylation was associated with significantly longer OS. The median OS was 7.03 (95% CI=7.58-18.44) months in those with non-methylated MGMT promoter ($\leq 40\%$) and 26.48 (95% CI=19.54-35.86) months in those with $>40\%$ MGMT promoter methylation, corresponding to an HR of 1.017 (95% CI=0.99-1.03, p=0.027), retrospectively. Patients with

higher postoperative KPS status (KPS>60%) also demonstrated increased OS, with 38.31 (95% CI=27.46-42.01) months versus 11.10 (95% CI=10.11-17.75) months for the other group, corresponding to an HR of 0.949 (95% CI=0.92-0.97, $p<0.001$).

4.2. MRI-based image-guided adaptive brachytherapy for locally advanced cervical cancer in clinical routine: a single-institution experience

The clinical data of 50 LACC patients treated with definitive CRT and IGABT boost between February 2016 and August 2022 at the Department of Oncotherapy University of Szeged were evaluated in our retrospective study. The average ($\pm SD$) age of the patients overall was 52.7 ± 12.6 years, ranging between 26 and 83 years. The median ($\pm SD$) overall treatment time was 53.8 ± 9.9 (range: 42–81) days. All patients had FIGO IB-IIIB stage LACC, 22 (44.0%) of them had negative lymph node status, and 28 (56.0%) were diagnosed with N1 disease. The vast majority of cases, 43 patients (86.0%), had squamous cell carcinoma, while seven patients (14.0%) had adenocarcinoma. Two-thirds of the study population was diagnosed with grade 2-3 tumors (Table 5). Of the 50 patients, 43 (86.0%) completed the scheduled five chemotherapy cycles, while seven (14.0%) received only four cycles of cisplatin. In the MRI-based IGABT group, among 24 patients, eight received combined the IC/IS IGABT treatment. Altogether, six patients had three BT sessions only due to dose limitations to the OARs: one in the MRI-based IGABT group and five in the CT-based treatment group. Histology, tumor grade, FIGO, and lymph node stage were well balanced between the two treatment groups. The features of the target volumes did not differ between the two groups; using the same EBRT technique, no significant difference was found between the coverage of PTV45, PTV-N, CTV-N_PIL, or CTV-N_PAQ of the two groups.

While the CTVHR volumes were similar, the D90 dose to them at BT was significantly higher in the MRI-based IGABT group than in the non-MRI-based group (7.37 ± 0.55 Gy vs. 6.87 ± 0.84 Gy, $p = 0.015$). The CTVHR D98 doses showed a strong trend in favor of the MRI-based technique (6.16 ± 0.59 Gy, vs. 5.72 ± 0.95 Gy, $p = 0.051$). Likewise, the cumulative doses to the CTVHR by means of both D90 and D98 were significantly higher in the MRI-based treatment group than in the other group (86.64 ± 4.76 Gy vs. 81.56 ± 8.29 Gy, $p = 0.011$ and 77.23 ± 4.39 Gy vs. 73.40 ± 7.80 Gy, $p = 0.037$, respectively). The Point A target doses, however, did not differ between the two groups. In the MRI-based IGABT group, an average EQD2 D98 dose of 8.01 ± 1.15 (5.3–10.2) Gy per BT session and 90.08 ± 11.99 Gy cumulative dose was delivered to the GTVres. When the doses to the CTVHR and GTVres within the MRI-

based IGABT group were compared according to the BT technique, no difference was found between the IC only and IC/IS cases.

The doses to the bladder, rectum, and sigmoid did not differ between the two groups. Interestingly, significantly less dose to the bowel was experienced in Group 2, both if the dose per BT fraction and the cumulative dose after EBRT and BT was considered. OAR doses in the MR-based IGABT cohort did not fluctuate over time.

Regarding treatment-related side effects, the most frequent acute toxicity of any grade was nausea, leucopenia, and neutropenia in both groups. There were no serious grade 3–4 adverse events registered. No cessation of the curative treatment course was necessary due to severe toxicity.

5. Discussion

5.1. *Adaptive Radiotherapy for Glioblastoma Multiforme - The Impact on Disease Outcome*

In accordance with the literature, our data confirm the impact of general prognostic factors on disease outcome, *i.e.* better KPS, larger extent of tumor removal and methylated MGMT promoter status resulted in longer survival. The optimal time interval between the surgery and start of CRT is a matter of debate in the literature and a clear conclusion cannot be drawn in our patient group, although the shorter time to CRT proved to be significant factor for better OS. Adaptive RT has mainly been applied in patients with extra-cranial localization taking into account anatomical changes associated with weight loss, internal organ movement, organ filling, tissue edema and potential tumor regression. These changes may significantly influence the dose distribution, resulting in target volume missing or overdosing in the OAR region. The studies published on ART have varied between daily onboard imaging-based plan adaptation and CT/MRI-based replanning prior to boost definition. The advantageous effect of replanning for brain irradiation is not yet supported by strong clinical evidence despite the increased attention to adaptive techniques and a growing amount of clinical data for tumors in other locations. Unlike extra-cranial localizations, data on ART for brain tumors is sparse in spite of the fact that GBM is known as a rapidly growing tumor type, and CRT is applied postoperatively when relevant changes in post-surgical and tumor volume are supposed to occur. According to the institutional strategy at our Oncotherapy Department, two-phase irradiation is planned with the shrinking-volume technique. A pre-therapeutic boost

definition is applied in conjunction with a recontouring of the residual tumor mass (GTV2) for repeated planning CT/MRI in an adapted CTV2-PTV2 approach. In our study, both the initial residual tumor volume and the extent of tumor shrinkage exhibited a significant impact on OS. The outcome of survival analysis showed no significant difference in terms of the initial size of the PTV. However, the GTV volume difference *i.e.* the difference between the GTV defined on the first plan and the tumorous mass seen on the replanning image, did show a significant correlation with OS in univariate analysis. Similarly, a relevant decrease in the size of the PTV (the PTV volume difference, analogous to the GTV volume difference) predicted better OS.

5.2. MRI-based image-guided adaptive brachytherapy for locally advanced cervical cancer in clinical routine: a single-institution experience

The studied IGABT technique based on multimodality imaging, modern radiobiology knowledge, and novel teletherapy and BT technologies is a rational approach but requires effort from the whole medical staff to adopt special skills and make a series of labor-intensive key steps in patient-management. For this new strategy, invaluable help is provided by the published protocol of the EMBRACE-II international clinical study. This book of precision on CRT and IGABT provides information on all challenges, including complex patient management, 3D image guidance, delineation and treatment planning, and proper BT applicator selection and arrangement. Due to the progression attributes of cervical carcinoma, sufficient loco-regional dose delivery is essential for tumor control. The review of Tanderup et al based on a large amount of clinical data demonstrated a strong correlation between the delivered dose to the target volumes and clinical outcome. The importance of dose escalation is also supported by the results of the EMBRACE-I study, achieving an excellent 5-year local control rate of 92% for the overall patient cohort. Our first series of patients and clinical data in this paper represent the efforts and learning period we went through during the integration of the modern IGART technique into our institutional practice. First, we systematically introduced the bladder protocol and rigid image fusion of the multiple series of treatment planning CT and diagnostic pelvic MRI and PET/CT scans for EBRT contouring, including the recommended complex volume of interest template, into the planning system. Accordingly, all patients received risk-adapted elective pelvic irradiation and SIB to pathological lymph nodes if applicable using IMRT planning aims; daily CBCT verification with correction to bony anatomy allowed for halving former PTV-CTV margins of 10 mm. Great attention was given to both teletherapy and chemotherapy as the basis of high-dose delivery at IGABT due to down-staging. Regarding the

implementation of MRI-guided IGABT, the greatest challenges were ensuring the infrastructure of anesthesia, appropriate patient transport, adequate MRI imaging, and applicator reconstruction during the first couple of combined IC/IS treatment sessions. Handling the early target delineation and planning optimization uncertainties, we could gradually improve the BT target dose utilizing MRI guidance, resulting in a mean dose to the D90 CTVHR higher than 85 Gy. Although in the first few cases our main goal was to safely remain within the limits of OAR hard-dose constraints, later on we simultaneously aimed at the fulfillment of OAR soft-dose constraints and the planning aims of D90 CTVHR (90–95 Gy) and D98 GTVres (>95 Gy). The only explanation why the target dose was higher in the MRI-guided IGABT group could be that by having had identified the residual tumor and delivered a prespecified radiation dose to it, the dose to the CTVHR was unintentionally increased too. Our experience on eight cases (16,0%) having received BT with interstitial needles was favorable, indicating that the combined IC/IS technique is the adequate solution to serve this dual goal. The analysis in the retroEMBRACE study suggested that the simple IC BT technique has limitations in CTVHR dose coverage, especially in cases with larger residual tumor volumes ($CTVHR > 30 \text{ cm}^3$), hence resulting in suboptimal local control. Another retroEMBRACE analysis by Fokdal et al. demonstrated that by using the combined IC/IS technique, the D90 CVTHR dose could be elevated by 9 Gy EQD₂ and consequently significantly higher local control rates were found in patients with residual $CTVHR > 30 \text{ cm}^3$ volumes without increasing toxicity as compared to the use of the sole IC BT technique. In fact, dedicated IC/IS applicators represent an excellent tool for the implementation of personalized treatment plans with unique complexity, allowing appropriate target coverage even if large residual tumors or parametrial infiltration are present. We have prospectively collected a set of acute toxicity measures possibly related to CRT; these were easily controlled and no serious side effects resulting in the cessation of therapy occurred.

6. Summary and conclusion

6.1. Our findings support the great importance of monitoring anatomical changes in the course of fractionated postoperative brain tumor irradiation. A follow-up of the residual tumor during CRT and adaptation of the PTV to tumor volume changes result in increased accuracy of dose delivery to the tumor and relevant normal brain tissue sparing. According to our data, reduction of the PTV did not compromise survival; in contrast, it seemed to be beneficial. Our preliminary data on improved survival on the basis of a higher degree of PTV reduction warrant further clinical studies to confirm these encouraging results.

The implementation of an ART approach is suggested for postoperative irradiation of GBM to optimize coverage of the target and minimize the dose to OARs. The reported data confirm that significant changes occur in different brain structures and in the residual tumor during fractionated CRT. The tumor response and adapted boost volume definition exhibited a strong correlation to treatment outcome. Optimization of the imaging (MRI and amino acid-based PET/CT) for replanning could further improve the quality of the adaptive approach.

6.2. In the exploratory analysis of our first clinical experience, we found that the MRI-based IGABT technique is feasible and appropriate both for individual dose escalation and control of OAR doses and toxicities in the curative treatment of LACC patients. As a key element of modern IGART delivery this should be the preferred approach, especially in cases with large and/or irregular extent post-teletherapy residual tumors.

7. Novel findings

- 7.1. The institutional protocol for target volume delineation in high-grade gliomas was retrospectively validated.
- 7.2. A significant correlation was identified between postoperative RT parameter (GTV) and OS of patients.
- 7.3. Significant anatomical changes were observed in various brain structures and in the residual tumor during the course of fractionated CRT, as confirmed by repeated imaging.
- 7.4. A strong correlation was demonstrated between tumor response, the definition of the adapted boost volume, and treatment outcome, underscoring the clinical relevance of ART approach in high-grade gliomas.
- 7.5. In cervical cancer cases, repeated MRI-based adaptive planning prior and during BT has resulted in significant target volume dose escalation and allowed for optimal protection of adjacent OARs.
- 7.6. The real-world process of successfully implementing the highly demanding EMBRACE-II protocol for curative cervical cancer RT is presented, demonstrating continuous improvements over time in imaging quality, target delineation, adaptive planning strategies and target dose coverage.

8. Acknowledgements

First of all I am most grateful to my supervisor, Professor Katalin Hideghéty, whose encouragement and generous support helped me in the completion of this work.

I express my sincere gratitude to Professor Judit Oláh, director of the Department of Oncotherapy, University of Szeged, who provided excellent working conditions for me at the institute.

I am greatly indebted to Professor Zsuzsanna Kahán, former director of the department, Zoltán Varga Ph.D. and Barbara Darázs Ph.D., whose invaluable support significantly contributed to my scientific work.

I am truly thankful for all the support and work of high standard provided by all the physicians, physicists and technician colleagues of the Department of Oncotherapy, University of Szeged that helped this dissertation to be born.

I am deeply grateful to my wife, family and parents for their unwavering support over the years.

List of full papers that served as the basis of the Ph.D. thesis

I. **Végváry Z, Darázs B, Paczona V, Dobi Á, Reisz Z, Varga Z, Fodor E, Cserháti A, Oláh J, Kis D, Barzó P, Hideghéty K.** Adaptive Radiotherapy for Glioblastoma Multiforme - The Impact on Disease Outcome.
Anticancer Res. 2020 Aug;40(8):4237-4244. doi: 10.21873/anticanres.14425.

IF: 2.480

II. **Végváry Z, Kószó R, Együd Z, Varga L, Paczona VR, Cserháti A, Gal V, Varga Z, Nagy Z, Deák B, Borzák F, Bontovics J, Fodor E, Oláh J, Kahán Z.** MRI-based image-guided adaptive brachytherapy for locally advanced cervical cancer in clinical routine: a single-institution experience.
Pathol Oncol Res. 2025 May 1;31:1612077. doi: 10.3389/pore.2025.1612077.

IF: 2.300